Update on the safety of itraconazole pulse therapy in onychomycosis and dermatomycoses.
As the use of newer antifungal agents becomes more widespread, safety issues surrounding their use have become more important. To date, the safety profile of itraconazole has been well defined by its worldwide use in 50 million patients over the past 13 years. Data from clinical practice and clinical trials indicate that the 1-week pulse regimen of itraconazole is well tolerated and associated with a favourable safety profile. Adverse events are generally mild and transient. Furthermore, a dose increase to 400 mg in the pulse regimen has had no adverse impact on safety.
Gupta
A
A
Department of Medicine, University of Toronto, Toronto, Canada. agupta@execulink.com
Lambert
J
J
Revuz
J
J
Shear
N
N
D000935:Antifungal Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D003881:Dermatomycoses / Q000188:drug therapy*; D006801:Humans; D017964:Itraconazole / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D008099:Liver / Q000187:drug effects; D014009:Onychomycosis / Q000188:drug therapy*; D020551:Pulse Therapy, Drug; D012867:Skin / Q000187:drug effects; D013649:Taste / Q000187:drug effects
D000935:Antifungal Agents; D017964:Itraconazole